Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 247 participants.

Also called NCT03529123

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 247 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03529123
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
India (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03529123. Randomized; no masking; primary purpose treatment. Start 2018-06-19 (actual); primary completion 2019-11-25 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010)
Intervention (Drug)
INSULIN GLARGINE (HOE901)
Intervention (Drug)
Metformin
Intervention (Drug)
Insulin Glulisine (HMR1964)
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct03529123
Content hash
dc84ebb181c5a9ff36ef508e822193a882522da68e9832736a24415d10afc174